Cargando…

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis

OBJECTIVE: Non-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite this, there has been limited evidence of it...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Chloe, Lee, Ming Hui, Yaow, Clyve Yu Leon, Chin, Yip Han, Goh, Xin Lei, Ng, Cheng Han, Lim, Amanda Yuan Ling, Muthiah, Mark Dhinesh, Khoo, Chin Meng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063104/ https://www.ncbi.nlm.nih.gov/pubmed/33897616 http://dx.doi.org/10.3389/fendo.2021.609110

Ejemplares similares

Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis
por: Wong, Chloe, et al.
Publicado: (2021)

The perspectives of health professionals and patients on racism in healthcare: A qualitative systematic review
por: Sim, Wilson, et al.
Publicado: (2021)

Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis
por: Dai, Yuzhao, et al.
Publicado: (2021)

A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota
por: Zhao, Li, et al.
Publicado: (2018)

It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Oberle, Megan M., et al.
Publicado: (2019)

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023)

Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
por: Sofogianni, Areti, et al.
Publicado: (2020)

Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study
por: Yan, Yilong, et al.
Publicado: (2023)

Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
por: Ghazanfar, Haider, et al.
Publicado: (2021)

Fasting and stimulated glucagon-like peptide-1 exhibit a compensatory adaptive response in diabetes and pre-diabetes states: A multi-ethnic comparative study
por: Chong, Shiau Chin, et al.
Publicado: (2022)

A Combination of Glucagon-Like Peptide-1 Receptor Agonist and Dietary Intervention Could Be a Promising Approach for Obesity Treatment
por: Lee, Chooi Yeng
Publicado: (2021)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Different position from traditional left lateral for colonoscopy? A meta-analysis and systematic review of randomized control trials
por: Lin, Snow Yunni, et al.
Publicado: (2020)

A Time-Based Meta-Analysis on the Incidence of New Onset Diabetes after Liver Transplantation
por: Chin, Yip Han, et al.
Publicado: (2021)

Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
por: Paternoster, Silvano, et al.
Publicado: (2018)

Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis
por: Yuan, Xia, et al.
Publicado: (2023)

Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data
por: Dong, Shichao, et al.
Publicado: (2022)

Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review
por: Xie, Zeyu, et al.
Publicado: (2023)

GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action
por: Lee, Seunghun P., et al.
Publicado: (2021)

Glucagon-like peptide-2 protects the gastric mucosa via regulating blood flow and metabolites
por: Zhang, Jing, et al.
Publicado: (2022)

Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China
por: Li, Cao, et al.
Publicado: (2022)

The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases
por: Chew, Nicholas W.S., et al.
Publicado: (2022)

Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease
por: Lee, Han Ah, et al.
Publicado: (2023)

SUN-236 Testosterone and Glucagon-Like Peptide-1 Agonists for Type 2 Diabetes Mellitus: A Prospective Cohort Study
por: Graybill, Sky
Publicado: (2019)

Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides
por: Sekar, Revathi, et al.
Publicado: (2017)

A Systematic Review of the Clinical Use of Gabapentin and Pregabalin in Bipolar Disorder
por: Ng, Qin Xiang, et al.
Publicado: (2021)

Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy
por: Valdecantos, M. Pilar, et al.
Publicado: (2018)

A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer
por: Chiu, Wei-Yih, et al.
Publicado: (2012)

SAT-570 Should Severe Hypertriglyceridemia Also Be Considered as a Contraindication for Use of Glucagon like Peptide 1 (GLP-1) Agonists?
por: Guzman, Amelia
Publicado: (2020)

PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis
por: Zhang, Zhuo-Ya, et al.
Publicado: (2023)

Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota
por: Wang, Ying, et al.
Publicado: (2021)

Corrigendum: Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides
por: Sekar, Revathi, et al.
Publicado: (2018)

Ghrelin Is a Regulator of Glucagon-Like Peptide 1 Secretion and Transcription in Mice
por: Lindqvist, Andreas, et al.
Publicado: (2017)

The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms
por: Zhao, Chenhe, et al.
Publicado: (2017)

Effect of Probiotic Supplementation on Gut Microbiota in Patients with Major Depressive Disorders: A Systematic Review
por: Ng, Qin Xiang, et al.
Publicado: (2023)

Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications
por: Körner, Meike, et al.
Publicado: (2012)

The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells
por: Marzook, Amaara, et al.
Publicado: (2021)

Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake
por: Ouberai, Myriam M., et al.
Publicado: (2023)

The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents
por: Vallöf, Daniel, et al.
Publicado: (2015)

Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review
por: Irfan, Huma, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_su4j54f9emklr016qd95j09brv